Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.55 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705162 | 1.00 | HRH3 (0.55) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL9906434 | 0.99 | HRH3 (0.53) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL17242530 | 0.96 | HRH3 (0.50) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL17531642 | 0.94 | DGAT1 (0.48) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL4111762 | 0.93 | DGAT1 (0.49) | HRH3DGAT1LTA4HCYP2D6CYP2C19 | |
| SCHEMBL30192619 | 0.91 | DGAT1 (0.47) | HRH3DGAT1ALDH1A1 | |
| SCHEMBL9906435 | 0.89 | DGAT1 (0.47) | HRH3DGAT1CYP2D6ALDH1A1KCNH2 | |
| SCHEMBL20844051 | 0.87 | DGAT1 (0.45) | HRH3DGAT1ALDH1A1KCNH2 | |
| SCHEMBL25358476 | 0.84 | HRH3 (0.46) | HRH3DGAT1CYP2D6KCNH2 | |
| SCHEMBL7879463 | 0.83 | DGAT1 (0.47) | DGAT1LTA4HKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114026097-B | Substituted pyrazoloquinazolinone compounds and uses thereof | 上海瑛派药业有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2023-09-14 | — | — | US | disclosed |
| CN-112752758-B | Imidazo [4,5-c ] cinnolin-2-one compounds as selective modulators of ATM kinase and uses thereof | 苏州赞荣医药科技有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | disclosed |
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2023-03-28 | — | — | US | disclosed |
| CN-115636833-A | Substituted imidazo [4,5-c ] cinnolin-2-one compounds as selective modulators of ATM kinases and uses thereof | 苏州赞荣医药科技有限公司 | 2023-01-24 | — | — | CN | disclosed |
| CN-110431139-B | Deuterated imidazo [4,5-c ] quinolin-2-one compounds and their use in treating cancer | 阿斯利康(瑞典)有限公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3683220-B1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF HUNTINGTON'S DISEASE | ASTRAZENECA AB (SE) | 2022-04-13 | — | — | EP | disclosed |
| US-20180141943-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141943-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2018-05-24 | — | — | US | disclosed |
| US-20180141943-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2018-05-24 | — | — | US | disclosed |
| US-9856255-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-01-02 | — | — | US | disclosed |
| US-9856255-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2018-01-02 | — | — | US | disclosed |
| WO-2017046216-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| WO-2017046216-A1 | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | WO | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11613539-B2 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer | ATM, BRCA1, CHEK2 | HRH3 2082/4885DGAT1 4514/4885LTA4H 4765/4885 |
| US-20230286981-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | HRH3 2082/4885DGAT1 4514/4885LTA4H 4765/4885 |
| US-20180141943-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | HRH3 2208/4885DGAT1 4538/4885LTA4H 4780/4885 |
| US-20170081325-A1 | Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer | ATM, BRCA1, CHEK2 | HRH3 2082/4885DGAT1 4514/4885LTA4H 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.